Skip to content
JNNP Podcast cover art

All Episodes

JNNP Podcast — 181 episodes · page 1 of 2

#
Title
1

Neurocognitive and psychiatric effects after mild COVID-19: meta-analytic evidence

2

Vestibular neurology for the generalist

3

Cyclophosphamide for myasthenia gravis: a comeback?

4

Management methods for acute ischaemic stroke

5

Distinguishing autoimmune nodopathies from CIDP, with Dr. Ruth Huizinga and Dr. Maarten Titulaer

6

Nutritional peripheral neuropathies, with Dr. Alexander Rossor

7

Distinguishing primary from functional tics

8

Nitrous Oxide Abuse

9

Brain Fog Demystified

10

A roadmap to ALS prevention: strategies and priorities

11

MOGAD: Definition, diagnosis and treatment

12

CGRP in migraine: current therapeutics, future implications and potential off-target effects

13

Alemtuzumab’s impact on functional and structural integrity of the visual system in MS

14

Guidelines for the management of functional speech and communication disorders

15

The impact of traumatic brain injury on neurocognitive outcomes in children

16

Cerebral Microbleeds: from depiction to interpretation

17

Motor functional neurological disease, a decade of progress

18

COVID - 19 Vaccination and risk of large vessel arterial stroke

19

Drug repurposing for progressive multiple sclerosis

20

Isaacs syndrome the crossroads of Neurology, Psychiatry and Immunology

21

Apathy, cerebral small vessel disease and future dementia risk

22

Performance validity tests - Their role in neuropsychology assessments

23

Parkinson’s disease: etiopathogenesis and treatment

24

Outcome measurement in functional neurological disorder a systematic review and recommendations

25

Clinical profiles of patients with dementia and chronic traumatic encephalopathy

26

Visual hallucinations in neurological and ophthalmological disease

27

Primary Lateral Sclerosis: new consensus criteria

28

Neurology in the time of COVID - 19

29

Lithium: a slow burner

30

Plasma glial fibrillary acidic protein is raised in progranulin-associated frontotemporal dementia

31

Multifocal motor neuropathy: controversies and priorities

32

Multiple Systems Atrophy: the nature of the beast revisited

33

Employment and MS - a patient’s perspective

34

Approaches to Chemotherapy induced peripheral neurotoxicity

35

Neural circuitry of anxiety

36

Dementia after traumatic brain injury

37

Mindfullness in multiple sclerosis

38

CIDP an update

39

Movement disorders and seizures

40

The role of functional neuroimaging in functional neurological disorders

41

Emotional processing in functional neurological disorder (FND)

42

Can cocoa help with fatigue in MS

43

Neurorehabilitation in chronic stroke

44

The real patient value

45

Medical conferences - what do we get out of them?

46

Oral immunotherapies in MS a comparison of efficacy.

47

Therapeutic trial design in frontotemporal dementias

48

Do genes affect age of onset in ALS?

49

The lifetime risk of common neurological disorders in the elderly population

50

PMA and PLS: are they really restricted phenotypes?

51

Statins and the risk of recurrent intracerebral haemorrhage (ICH) – what does the evidence say?

52

Functional impairment and improvement

53

Can computational models help us understand complex movement disorders?

54

Idiopathic intracranial hypertension: guidelines for diagnosis and management

55

Nusinersen for SMA

56

Expanding clinical spectrums in both Kennedy’s disease and poststroke syndromes

57

The use of cannabis in epilepsy, and surgery for tremor

58

Epilepsy an evidence update

59

Evolution or revolution? Should we re-think clinical practice?

60

The Use of Frankincense Extract In MS

61

A new questionnaire to measure quality of life in inflammatory neuropathies

62

Marriage and a reduced risk of dementia

63

Anti-inflammatory approaches to stroke prevention; monitoring disease progression in ALS

64

Nodes and paranodes; alternative treatments in MS

65

Pathophysiology of functional neurological disorder

66

Is methamphetamine use linked to stroke in young adults?

67

Cerebral Amyloid Angiopathy: New Insights For Clinical Practice

68

Cortical Influences in ALS

69

Intravenous immunoglobulin in CIDP

70

Complex inherited neuropathies: a new approach to diagnosis?

71

Cerebellum and neurodegeneration; autoantibodies and psychological development in children

72

Time Matters - part 2: how the real costs of multiple sclerosis are being concealed

73

Survival and cause of death in Multiple Sclerosis

74

Time Matters - part 1: delay is “expensive” in all aspects of multiple sclerosis

75

Seven tesla MRI In Neurodegenerative Dementias

76

Conversational Laughter In Dementia

77

Narrative and Neurology: The Andrew Lees Experiment

78

April 2017: deconstructing dilemmas in Amyotrophic Lateral Sclerosis and Guillain-Barré Syndrome

79

Zika virus and Guillain-Barré Syndrome: what do we know?

80

Immunomodulatory therapy in advanced multiple sclerosis

81

The relationship between orthostatic hypotension and cognitive impairment in α-synucleinopathies

82

A clinical tool for predicting survival in motor neurone disease

83

Latitude and disease severity in Multiple Sclerosis

84

Do your kids play rugby? Risks for rugby union players from repeated concussions

85

Genetics and the clinical course of multiple sclerosis

86

Is it time to focus on the common pathways linking neurodegenerative diseases?

87

October 2016 Edition: long-term outcomes after stroke; hereditary and inflammatory neuropathies

88

Selective vulnerability in clinical variants of Alzheimer’s Disease

89

Smoking: a negative prognostic for survival in motor neurone disease patients

90

Review: Amyotrophic Lateral Sclerosis and Motor Neuron Syndromes in Asia

91

Automated brain volumetrics in multiple sclerosis, plus migraine and psychiatric co-morbidities

92

Coffee consumption and multiple sclerosis

93

June Edition: Parkinson’s disease and the rate of ALS progression

94

Sudden Unexpected Death in Epilepsy: basic mechanisms and implications for prevention

95

Re-evaluating the treatment of acute optic neuritis

96

BNPA 2015: Spatial Neglect

97

BNPA 2015: New theories of memory systems and networks

98

BNPA 2015: Phantom phenomena

99

Clinical neurology: why this still matters in the 21st century

100

Imaging outcomes for trials of remyelination in multiple sclerosis